From serotonin to neuroplasticity: Evolvement of theories for major depressive disorder

Frontiers in Cellular Neuroscience

Volumn 11, Issue , 2017, Pages

  Liu, Bangshan ^a   Liu, Jin ^a   Wang, Mi ^a   Zhang, Yan ^a   Li, Lingjiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Antidepressant efficacy; Final common pathway; Major depressive disorder; Neuroplasticity; Serotonin

Indexed keywords

AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ELONGATION FACTOR 2; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; KETAMINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; VOLTAGE GATED CALCIUM CHANNEL;

CELL MEMBRANE DEPOLARIZATION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; FUNCTIONAL NEUROIMAGING; GENETIC ASSOCIATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PATHOGENESIS; PREFRONTAL CORTEX; RECEPTOR DOWN REGULATION; REVIEW; STRIA TERMINALIS; SYNAPTIC TRANSMISSION; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; VENTRAL TEGMENTUM;

EID: 85031997514     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2017.00305     Document Type: Review

References (84)

1. Abraham, W. C. (2008). Metaplasticity: tuning synapses and networks for plasticity. Nat. Rev. Neurosci. 9:387. doi: 10.1038/nrn2356
2. Abraham, W. C., and Bear, M. F. (1996). Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci. 19, 126-130. doi: 10.1016/s0166-2236(96)80018-x
3. American Psychiatric Association Work Group on Major Depressive Disorder. (2010). Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd Edn. Washington, DC: American Psychiatric Association Press.
4. Amital, D., Fostick, L., Silberman, A., Beckman, M., and Spivak, B. (2008). Serious life events among resistant and non-resistant MDD patients. J. Affect. Disord. 110, 260-264. doi: 10.1016/j.jad.2008.01.006
5. Andrade, C., and Rao, N. S. (2010). How antidepressant drugs act: a primer on neuroplasticity as the eventual mediator of antidepressant efficacy. Indian J. Psychiatry 52, 378-386. doi: 10.4103/0019-5545.74318
6. Andrews, P. W., Bharwani, A., Lee, K. R., Fox, M., and Thomson, J. A. Jr.. (2015). Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response. Neurosci. Biobehav. Rev. 51, 164-188. doi: 10.1016/j.neubiorev.2015.01.018
7. Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H. J., et al. (2013). World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J. Biol. Psychiatry 14, 334-385. doi: 10.3109/15622975.2013.804195
8. Bekris, S., Antoniou, K., Daskas, S., and Papadopoulou-Daifoti, Z. (2005). Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. Behav. Brain Res. 161, 45-59. doi: 10.1016/j.bbr.2005.01.005
9. Biegler, P. (2008). Autonomy, stress, and treatment of depression. BMJ 336, 1046-1048. doi: 10.1136/bmj.39541.470023.ad
10. Binder, E. B., and Nemeroff, C. B. (2010). The CRF system, stress, depression and anxiety—insights from human genetic studies. Mol. Psychiatry 15, 574-588. doi: 10.1038/mp.2009.141
11. Bonanno, G., Giambelli, R., Raiteri, L., Tiraboschi, E., Zappettini, S., Musazzi, L., et al. (2005). Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J. Neurosci. 25, 3270-3279. doi: 10.1523/jneurosci.5033-04.2005
12. Bosker, F. J., Tanke, M. A., Jongsma, M. E., Cremers, T. I., Jagtman, E., Pietersen, C. Y., et al. (2010). Biochemical and behavioral effects of long-term citalopram administration and discontinuation in rats: role of serotonin synthesis. Neurochem. Int. 57, 948-957. doi: 10.1016/j.neuint.2010.10.001
13. Browne, C. A., and Lucki, I. (2013). Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front. Pharmacol. 4:161. doi: 10.3389/fphar.2013.00161
14. Carlezon, W. A. Jr., Duman, R. S., and Nestler, E. J. (2005). The many faces of CREB. Trends Neurosci. 28, 436-445. doi: 10.1016/j.tins.2005.06.005
15. Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., et al. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389. doi: 10.1126/science.1083968
16. Collins, P. Y., Patel, V., Joestl, S. S., March, D., Insel, T. R., Daar, A. S., et al. (2011). Grand challenges in global mental health. Nature 475, 27-30. doi: 10.1038/475027a
17. Coppen, A. (1967). The biochemistry of affective disorders. Br. J. Psychiatry 113, 1237-1264. doi: 10.1192/bjp.113.504.1237
18. Cramer, S. C., Sur, M., Dobkin, B. H., O’Brien, C., Sanger, T. D., Trojanowski, J. Q., et al. (2011). Harnessing neuroplasticity for clinical applications. Brain 134, 1591-1609. doi: 10.1093/brain/awr039
19. Czéh, B., Fuchs, E., Wiborg, O., and Simon, M. (2016). Animal models of major depression and their clinical implications. Prog. Neuropsychopharmacol. Biol. Psychiatry 64, 293-310. doi: 10.1016/j.pnpbp.2015.04.004
20. Davies, D. L., and Shepherd, M. (1955). Reserpine in the treatment of anxious and depressed patients. Lancet 266, 117-120. doi: 10.1016/s0140-6736(55)92118-8
21. de Kloet, E. R., Joëls, M., and Holsboer, F. (2005). Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. 6, 463-475. doi: 10.1038/nrn1683
22. Douglas, R. J., and Martin, K. A. (2007). Mapping the matrix: the ways of neocortex. Neuron 56, 226-238. doi: 10.1016/j.neuron.2007.10.017
23. Du, J., Machado-Vieira, R., Maeng, S., Martinowich, K., Manji, H. K., Zarate, C. A. Jr.. (2006). Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discov. Today Ther. Strateg. 3, 519-526. doi: 10.1016/j.ddstr.2006.11.012
24. Duman, R. S. (2004). Depression: a case of neuronal life and death? Biol. Psychiatry 56, 140-145. doi: 10.1016/j.biopsych.2004.02.033
25. Egeland, M., Zunszain, P. A., and Pariante, C. M. (2015). Molecular mechanisms in the regulation of adult neurogenesis during stress. Nat. Rev. Neurosci. 16, 189-200. doi: 10.1038/nrn3855
26. Fischer, A. G., Jocham, G., and Ullsperger, M. (2014). Dual serotonergic signals: a key to understanding paradoxical effects? Trends Cogn. Sci. doi: 10.1016/j.tics.2014.11.004 [Epub ahead of print].
27. Gilman, S. E., Trinh, N. H., Smoller, J. W., Fava, M., Murphy, J. M., and Breslau, J. (2013). Psychosocial stressors and the prognosis of major depression: a test of Axis IV. Psychol. Med. 43, 303-316. doi: 10.1017/s0033291712001080
28. Grafman, J. (2000). Conceptualizing functional neuroplasticity. J. Commun. Disord. 33, 345-355; quiz 355-346. doi: 10.1016/s0021-9924(00)00030-7
29. Hammen, C. (2005). Stress and depression. Annu. Rev. Clin. Psychol. 1, 293-319. doi: 10.1146/annurev.clinpsy.1.102803.143938
30. Harkness, K. L., Theriault, J. E., Stewart, J. G., and Bagby, R. M. (2014). Acute and chronic stress exposure predicts 1-year recurrence in adult outpatients with residual depression symptoms following response to treatment. Depress. Anxiety 31, 1-8. doi: 10.1002/da.22177
31. Harmer, C. J., and Cowen, P. J. (2013). ‘It’s the way that you look at it’—a cognitive neuropsychological account of SSRI action in depression. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368:20120407. doi: 10.1098/rstb.2012.0407
32. Hayley, S., and Litteljohn, D. (2013). Neuroplasticity and the next wave of antidepressant strategies. Front. Cell. Neurosci. 7:218. doi: 10.3389/fncel.2013.00218
33. Hirschfeld, R. M. A. (2000). History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 61, 4-6.
34. Holsboer, F. (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23, 477-501. doi: 10.1016/s0893-133x(00)00159-7
35. Holsboer, F., and Barden, N. (1996). Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17, 187-205. doi: 10.1210/er.17.2.187
36. Hulme, S. R., Jones, O. D., and Abraham, W. C. (2013). Emerging roles of metaplasticity in behaviour and disease. Trends Neurosci. 36, 353-362. doi: 10.1016/j.tins.2013.03.007
37. Jentsch, M. C., Van Buel, E. M., Bosker, F. J., Gladkevich, A. V., Klein, H. C., Oude Voshaar, R. C., et al. (2015). Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. Biomark. Med. 9, 277-297. doi: 10.2217/bmm.14.114
38. Karg, K., Burmeister, M., Shedden, K., and Sen, S. (2011). The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiatry 68, 444-454. doi: 10.1001/archgenpsychiatry.2010.189
39. Kasper, S., and McEwen, B. S. (2008). Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 22, 15-26. doi: 10.2165/00023210-200822010-00002
40. Kavalali, E. T., and Monteggia, L. M. (2015). How does ketamine elicit a rapid antidepressant response? Curr. Opin. Pharmacol. 20, 35-39. doi: 10.1016/j.coph.2014.11.005
41. Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., et al. (2016). Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can. J. Psychiatry 61, 540-560. doi: 10.1177/0706743716659417
42. Kuhn, R. (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). Am. J. Psychiatry 115, 459-464. doi: 10.1176/ajp.115.5.459
43. Lacasse, J. R., and Leo, J. (2005). Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2:e392. doi: 10.1371/journal.pmed.0020392
44. Lapin, I. P., and Oxenkrug, G. F. (1969). Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1, 132-136. doi: 10.1016/s0140-6736(69)91140-4
45. MacQueen, G., and Frodl, T. (2011). The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol. Psychiatry 16, 252-264. doi: 10.1038/mp.2010.80
46. Mahar, I., Bambico, F. R., Mechawar, N., and Nobrega, J. N. (2014). Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci. Biobehav. Rev. 38, 173-192. doi: 10.1016/j.neubiorev.2013.11.009
47. Marsteller, D. A., Barbarich-Marsteller, N. C., Patel, V. D., and Dewey, S. L. (2007). Brain metabolic changes following 4-week citalopram infusion: increased 18FDG uptake and γ-amino butyric acid levels. Synapse 61, 877-881. doi: 10.1002/syn.20428
48. Martinez-Turrillas, R., Frechilla, D., and Del Río, J. (2002). Chronic antidepressant treatment increases the membrane expression of AMPA receptors in rat hippocampus. Neuropharmacology 43, 1230-1237. doi: 10.1016/s0028-3908(02)00299-x
49. Monroe, S. M., and Harkness, K. L. (2005). Life stress, the “kindling” hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol. Rev. 112, 417-445. doi: 10.1037/0033-295x.112.2.417
50. Monteggia, L. M., Gideons, E., and Kavalali, E. T. (2013). The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol. Psychiatry 73, 1199-1203. doi: 10.1016/j.biopsych.2012.09.006
51. Mulinari, S. (2012). Monoamine theories of depression: historical impact on biomedical research. J. Hist. Neurosci. 21, 366-392. doi: 10.1080/0964704X.2011.623917
52. Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., et al. (2013). Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry 74, 250-256. doi: 10.1016/j.biopsych.2012.06.022
53. National Institute for Health and Care Excellence. (2009). Depression in adults: recognition and management. Available online at: https://www.nice.org.uk/guidance/cg90/chapter/1-Guidance-stepped-care. [Accessed on January 12, 2017].
54. Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., et al. (2015). Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am. J. Psychiatry 172, 950-966. doi: 10.1176/appi.ajp.2015.15040465
55. Oswald, I., Brezinova, V., and Dunleavy, D. L. F. (1972). On the slowness of action of tricyclic antidepressant drugs. Br. J. Psychiatry 120, 673-677. doi: 10.1192/bjp.120.559.673
56. Paul, I. A., and Skolnick, P. (2003). Glutamate and depression: clinical and preclinical studies. Ann. N Y Acad. Sci. 1003, 250-272. doi: 10.1196/annals.1300.016
57. Phillips, M. L., Chase, H. W., Sheline, Y. I., Etkin, A., Almeida, J. R., Deckersbach, T., et al. (2015). Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am. J. Psychiatry 172, 124-138. doi: 10.1176/appi.ajp.2014.14010076
58. Pittenger, C., and Duman, R. S. (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33, 88-109. doi: 10.1038/sj.npp.1301574
59. Pizzagalli, D. A. (2014). Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu. Rev. Clin. Psychol. 10, 393-423. doi: 10.1146/annurev-clinpsy-050212-185606
60. Popoli, M., Gennarelli, M., and Racagni, G. (2002). Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord. 4, 166-182. doi: 10.1034/j.1399-5618.2002.01159.x
61. Racagni, G., and Popoli, M. (2008). Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin. Neurosci. 10, 385-400.
62. Rial, D., Lemos, C., Pinheiro, H., Duarte, J. M., Gonçalves, F. Q., Real, J. I., et al. (2015). Depression as a glial-based synaptic dysfunction. Front. Cell. Neurosci. 9:521. doi: 10.3389/fncel.2015.00521
63. Risch, N., Herrell, R., Lehner, T., Liang, K. Y., Eaves, L., Hoh, J., et al. (2009). Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301, 2462-2471. doi: 10.1001/jama.2009.878
64. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. (2004). Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust. N Z J. Psychiatry 38, 389-407. doi: 10.1111/j.1440-1614.2004.01377.x
65. Ruhé, H. G., Mason, N. S., and Schene, A. H. (2007). Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12, 331-359. doi: 10.1038/sj.mp.4001949
66. Ruhé, H. G., Visser, A. K. D., Frokjaer, V. G., Haarman, B. C. M., Klein, H. C., and Booij, J. (2014). “Molecular imaging of depressive disorders,” in PET and SPECT in Psychiatry, eds R. A. J. O. Dierckx, A. Otte, E. F. J. de Vries, A. van Waarde, and J. A. den Boer (Berlin, Heidelberg: Springer), 93-172.
67. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905-1917. doi: 10.1176/appi.ajp.163.11.1905
68. Sanacora, G., Treccani, G., and Popoli, M. (2012). Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62, 63-77. doi: 10.1016/j.neuropharm.2011.07.036
69. Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805-809. doi: 10.1126/science.1083328
70. Scheuing, L., Chiu, C. T., Liao, H. M., and Chuang, D. M. (2015). Antidepressant mechanism of ketamine: perspective from preclinical studies. Front. Neurosci. 9:249. doi: 10.3389/fnins.2015.00249
71. Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122, 509-522. doi: 10.1176/ajp.122.5.509
72. Schildkraut, J. J., and Kety, S. S. (1967). Biogenic amines and emotion. Science 156, 21-37. doi: 10.1126/science.156.3771.21
73. Selikoff, I. J., Robitzek, E. H., and Ornstein, G. G. (1952). Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. J. Am. Med. Assoc. 150, 973-980.
74. Serafini, G. (2012). Neuroplasticity and major depression, the role of modern antidepressant drugs. World J. Psychiatry 2, 49-57. doi: 10.5498/wjp.v2.i3.49
75. Shakesby, A. C., Anwyl, R., and Rowan, M. J. (2002). Overcoming the effects of stress on synaptic plasticity in the intact hippocampus: rapid actions of serotonergic and antidepressant agents. J. Neurosci. 22, 3638-3644.
76. Siesser, W. B., Sachs, B. D., Ramsey, A. J., Sotnikova, T. D., Beaulieu, J. M., Zhang, X., et al. (2013). Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice. ACS Chem. Neurosci. 4, 84-88. doi: 10.1021/cn300127h
77. Stahl, S. M. (1984). Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action. J. Clin. Psychiatry 45, 37-45.
78. Stahl, S. M. (2013). Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th Edn. Cambridge, MA: Cambridge University Press.
79. Thomas, E. J., and Elliott, R. (2009). Brain imaging correlates of cognitive impairment in depression. Front. Hum. Neurosci. 3:30. doi: 10.3389/neuro.09.030.2009
80. Vose, L. R., and Stanton, P. K. (2017). Synaptic plasticity, metaplasticity and depression. Curr. Neuropharmacol. 15, 71-86. doi: 10.2174/1570159x14666160202121111
81. World Health Organization. (2016). Depression: fact sheet. Available online at: http://www.who.int/mediacentre/factsheets/fs369/en/
82. Yoshii, A., and Constantine-Paton, M. (2010). Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev. Neurobiol. 70, 304-322. doi: 10.1002/dneu.20765
83. Young, E., and Korszun, A. (2010). Sex, trauma, stress hormones and depression. Mol. Psychiatry 15, 23-28. doi: 10.1038/mp.2009.94
84. Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M. M., and Pariante, C. M. (2013). Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol. Psychiatry 18, 1236-1241. doi: 10.1038/mp.2013.87